{
    "2019-10-24": [
        [
            {
                "time": "",
                "original_text": "【民生医药】医药生物2019年三季报总结：基本面进入值得期待的新周期",
                "features": {
                    "keywords": [
                        "医药生物",
                        "三季报",
                        "基本面",
                        "新周期"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "逾540亿解禁股来袭 130家公司解禁市值超10亿元 解禁",
                "features": {
                    "keywords": [
                        "解禁股",
                        "市值",
                        "公司"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}